195 related articles for article (PubMed ID: 26519222)
1. Binding Mode Selection Determines the Action of Ecstasy Homologs at Monoamine Transporters.
Sandtner W; Stockner T; Hasenhuetl PS; Partilla JS; Seddik A; Zhang YW; Cao J; Holy M; Steinkellner T; Rudnick G; Baumann MH; Ecker GF; Newman AH; Sitte HH
Mol Pharmacol; 2016 Jan; 89(1):165-75. PubMed ID: 26519222
[TBL] [Abstract][Full Text] [Related]
2. Neurochemical binding profiles of novel indole and benzofuran MDMA analogues.
Shimshoni JA; Winkler I; Golan E; Nutt D
Naunyn Schmiedebergs Arch Pharmacol; 2017 Jan; 390(1):15-24. PubMed ID: 27650729
[TBL] [Abstract][Full Text] [Related]
3. N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability.
Solis E; Partilla JS; Sakloth F; Ruchala I; Schwienteck KL; De Felice LJ; Eltit JM; Glennon RA; Negus SS; Baumann MH
Neuropsychopharmacology; 2017 Sep; 42(10):1950-1961. PubMed ID: 28530234
[TBL] [Abstract][Full Text] [Related]
4. Binding of the amphetamine-like 1-phenyl-piperazine to monoamine transporters.
Severinsen K; Kraft JF; Koldsø H; Vinberg KA; Rothman RB; Partilla JS; Wiborg O; Blough B; Schiøtt B; Sinning S
ACS Chem Neurosci; 2012 Sep; 3(9):693-705. PubMed ID: 23019496
[TBL] [Abstract][Full Text] [Related]
5. Lobeline analogs with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters.
Miller DK; Crooks PA; Zheng G; Grinevich VP; Norrholm SD; Dwoskin LP
J Pharmacol Exp Ther; 2004 Sep; 310(3):1035-45. PubMed ID: 15121762
[TBL] [Abstract][Full Text] [Related]
6. Emulating proton-induced conformational changes in the vesicular monoamine transporter VMAT2 by mutagenesis.
Yaffe D; Vergara-Jaque A; Forrest LR; Schuldiner S
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):E7390-E7398. PubMed ID: 27821772
[TBL] [Abstract][Full Text] [Related]
7. The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter.
Pifl C; Reither H; Hornykiewicz O
Eur J Pharmacol; 2015 May; 755():119-26. PubMed ID: 25771452
[TBL] [Abstract][Full Text] [Related]
8. Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity.
Biezonski DK; Meyer JS
J Neurochem; 2010 Feb; 112(4):951-62. PubMed ID: 20002520
[TBL] [Abstract][Full Text] [Related]
9. Vesicular monoamine transporter 2 and the acute and long-term response to 3,4-(±)-methylenedioxymethamphetamine.
Lizarraga LE; Cholanians AB; Phan AV; Herndon JM; Lau SS; Monks TJ
Toxicol Sci; 2015 Jan; 143(1):209-19. PubMed ID: 25370842
[TBL] [Abstract][Full Text] [Related]
10. Identification of an allosteric modulator of the serotonin transporter with novel mechanism of action.
Kortagere S; Fontana AC; Rose DR; Mortensen OV
Neuropharmacology; 2013 Sep; 72():282-90. PubMed ID: 23632081
[TBL] [Abstract][Full Text] [Related]
11. [Mass spectrometry data of some metabolites of the amphetamine derivatives 3,4-(methylenedioxy) amphetamine (MDA) and 3,4-methylenedioxy)methylamphetamine (MDMA)].
Verweij AM
Arch Kriminol; 1996; 197(1-2):27-30. PubMed ID: 8851250
[TBL] [Abstract][Full Text] [Related]
12. Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines.
Montgomery T; Buon C; Eibauer S; Guiry PJ; Keenan AK; McBean GJ
Br J Pharmacol; 2007 Dec; 152(7):1121-30. PubMed ID: 17891159
[TBL] [Abstract][Full Text] [Related]
13. Pyrrolidine analogues of lobelane: relationship of affinity for the dihydrotetrabenazine binding site with function of the vesicular monoamine transporter 2 (VMAT2).
Vartak AP; Nickell JR; Chagkutip J; Dwoskin LP; Crooks PA
J Med Chem; 2009 Dec; 52(23):7878-82. PubMed ID: 19691331
[TBL] [Abstract][Full Text] [Related]
14. The ins and outs of vesicular monoamine transporters.
Yaffe D; Forrest LR; Schuldiner S
J Gen Physiol; 2018 May; 150(5):671-682. PubMed ID: 29666153
[TBL] [Abstract][Full Text] [Related]
15. The pharmacological profile of the vesicular monoamine transporter resembles that of multidrug transporters.
Yelin R; Schuldiner S
FEBS Lett; 1995 Dec; 377(2):201-7. PubMed ID: 8543051
[TBL] [Abstract][Full Text] [Related]
16. Phenyl ring-substituted lobelane analogs: inhibition of [³H]dopamine uptake at the vesicular monoamine transporter-2.
Nickell JR; Zheng G; Deaciuc AG; Crooks PA; Dwoskin LP
J Pharmacol Exp Ther; 2011 Mar; 336(3):724-33. PubMed ID: 20876747
[TBL] [Abstract][Full Text] [Related]
17. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.
Verrico CD; Miller GM; Madras BK
Psychopharmacology (Berl); 2007 Jan; 189(4):489-503. PubMed ID: 16220332
[TBL] [Abstract][Full Text] [Related]
18. Chronic and acute effects of 3,4-methylenedioxy-N-methylamphetamine ('Ecstasy') administration on the dynorphinergic system in the rat brain.
Di Benedetto M; D'addario C; Candeletti S; Romualdi P
Neuroscience; 2006; 137(1):187-96. PubMed ID: 16289352
[TBL] [Abstract][Full Text] [Related]
19. Identification of the substrate binding region of vesicular monoamine transporter-2 (VMAT-2) using iodoaminoflisopolol as a novel photoprobe.
Gopalakrishnan A; Sievert M; Ruoho AE
Mol Pharmacol; 2007 Dec; 72(6):1567-75. PubMed ID: 17766642
[TBL] [Abstract][Full Text] [Related]
20. Vesicular monoamine transporter 2: role as a novel target for drug development.
Zheng G; Dwoskin LP; Crooks PA
AAPS J; 2006 Nov; 8(4):E682-92. PubMed ID: 17233532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
